DexCom Files 8-K Amendment on Officer/Director Changes

Ticker: DXCM · Form: 8-K/A · Filed: 2025-05-09T00:00:00.000Z

Sentiment: neutral

Topics: officer-changes, director-changes, amendment

Related Tickers: DXCM

TL;DR

DexCom filed an 8-K amendment regarding leadership changes. Keep an eye on who's in and out.

AI Summary

DexCom, Inc. filed an amendment (8-K/A) on May 9, 2025, to its report originally dated March 6, 2025. The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Specific details regarding these changes were not provided in the excerpt.

Why It Matters

This filing indicates potential shifts in the leadership or compensation structure of DexCom, which could impact the company's strategic direction and governance.

Risk Assessment

Risk Level: medium — Amendments to 8-K filings concerning officer and director changes can signal internal shifts that may affect company strategy or stability.

Key Players & Entities

FAQ

What specific officer or director changes are detailed in this 8-K/A filing?

The provided text indicates the filing is an amendment related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements, but does not specify the individuals or exact changes.

What was the original report date for this filing?

The original report date was March 6, 2025.

When was this amendment (8-K/A) filed?

This amendment was filed on May 9, 2025.

What is the principal executive office address for DexCom, Inc.?

The principal executive office address is 6340 Sequence Drive, San Diego, CA 92121.

What is DexCom, Inc.'s telephone number?

DexCom, Inc.'s telephone number is (858) 200-0200.

From the Filing

0001093557-25-000134.txt : 20250509 0001093557-25-000134.hdr.sgml : 20250509 20250509162031 ACCESSION NUMBER: 0001093557-25-000134 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250306 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250509 DATE AS OF CHANGE: 20250509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 25930737 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K/A 1 dxcm-20250306.htm 8-K/A dxcm-20250306 false 0001093557 0001093557 2025-03-06 2025-03-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K/A (Amendment No. 1)   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On March 10, 2025, DexCom, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) to announce, among other things, the appointment of Ms. Renée Galá to the Company’s board of directors (the “Board”), effective March 6, 2025. At the time the Initial Form 8-K was filed, the Board had not yet determined on which Board committees, if any, Ms. Galá would serve. This Amendment No. 1 to the Initial Form 8-K is being filed to report that on May 9, 2025, the Board appointed Ms. Galá to serve as a member of the Audit Committee and the Compensation Committee of the Board,

View on Read The Filing